What does this company do and how does it make money?

Axon has transformed from a TASER manufacturer into a software-first law enforcement technology company. The shift to recurring software revenue (now 60.8% of sales) with 125% net retention suggests strong customer stickiness, though heavy US concentration creates both focus and vulnerability.

Five legendary investment frameworks analyzed this company.

Buffett sees shareholders being sold as the product with 26.2% dilution rates, while Lynch spots a fast grower worth stretching for — but at 3,805x earnings, even the optimist admits the PEG exceeds 100. Tap any framework below to explore their complete analysis.

How much cash does it generate and where does it go?

Cash generation remains modest at $75M FCF while capital allocation shows aggressive growth priorities: R&D consumes 61.7% of operating cash flow and Q4'25 saw $624M in acquisitions. The 26.2% stock compensation rate means shareholders fund expansion through dilution rather than retained earnings.

Is the business getting stronger or weaker?

The business shows contradictory signals: revenue surges 33.5% but operating margins compress to 1.3%, suggesting growth comes at increasing cost. The 0.10 operating leverage coefficient reveals minimal profit expansion despite rapid top-line growth, while lengthening cash cycles indicate operational strain.

What could go wrong and has it survived trouble before?

Axon survived COVID's 17.8% revenue hit and recovered within 2 quarters, demonstrating resilience. Current risks include sustained insider selling during growth acceleration, rising leverage (debt-to-equity at 88th percentile), and heavy concentration in both product mix and geography.

When stock compensation consumes 26.2% of revenue, shareholders are funding growth with their own dilution.

Is the stock priced for perfection, fair value, or pessimism?

At 3,805x earnings with a 0.66% yield versus 4.33% treasuries, the market prices in extraordinary future performance. Trading 558% above DCF value while implying only 10.68% perpetual growth suggests the market expects growth deceleration from current 33.5% levels but still assigns an extreme premium.